Strong Growth Predicted for Multivalent Vaccines Global Market, Set to Reach $12.16 Billion by 2028

November 25, 2024 07:30 PM AEDT | By EIN Presswire
 Strong Growth Predicted for Multivalent Vaccines Global Market, Set to Reach $12.16 Billion by 2028
Image source: EIN Presswire

LONDON, GREATER LONDON, UNITED KINGDOM, November 25, 2024 /EINPresswire.com/ -- The Business Research Company’s Early Year-End Sale! Get up to 30% off detailed market research reports—limited time only!

The multivalent vaccines market has seen impressive growth in recent years, surging from $7.63 billion in 2023 to $8.37 billion in 2024 at a compound annual growth rate CAGR of 9.7%. This marked escalation can be linked to aspects such as a rising public awareness for vaccination, increasing government support, growing demand for pediatric multivalent vaccines, and boosted funding for vaccine research.

How Is the Multivalent Vaccines Market Size Projected to Evolve in Future?

The multivalent vaccines sector is slated to display robust growth over the coming years. Projections suggest that it will expand to $12.16 billion by 2028 at a CAGR of 9.8%. This forecasted growth can be attributed to factors including a rising incidence of infectious diseases, a growing geriatric population, increased government and private sector investment, and an enhanced focus on vaccine safety and effectiveness. Major discernable market trends for the forecast period encompass a greater focus on combination vaccines, integration of digital health technologies, developments in mRNA technology, the evolution of personalized vaccines, and an increase in research activities.

Find an extensive sample report with comprehensive insights into the multivalent vaccines market here: https://www.thebusinessresearchcompany.com/sample.aspx?id=19120&type=smp

What Are the Primary Drivers of the Multivalent Vaccines Market?

Growth in the multivalent vaccines market is set to be propelled forward by rising incidences of infectious diseases. These illnesses are caused by perturbing pathogens including bacteria, viruses, fungi, and parasites that spread via direct contact or contaminated surfaces, air, or water. Conditions can range from mild to severe, and global travel has been instrumental in accelerating the spread of infectious diseases by swiftly crossing borders to infect new populations. Multivalent vaccines offer a broad defense against infectious diseases, targeting multiple pathogen strains in one dose and thus eliminating the necessity for separate shots. This broad coverage aids herd immunity and lowers disease prevalence, ultimately bolstering public health. For instance, an April 2024 report by TravelHealthPro showcased the UK’s increase in reported malaria cases from 1,369 in 2022 to 2,004 in 2023, thereby highlighting a growth in infectious diseases.

Pre-book the comprehensive report for swift delivery here: https://www.thebusinessresearchcompany.com/report/multivalent-vaccines-global-market-report

Which Notable Developments and Trends Are Influencing the Multivalent Vaccines Market?

Pivotal players in the multivalent vaccines market are steering their focus towards developing advanced pentavalent vaccines, which guard against five distinct pathogens or strains. This combination method simplifies immunization schedules and provides comprehensive vaccine coverage. Case in point is India-based biotechnology firm, Panacea Biotec Ltd., who in December 2023 launched the world’s first fully liquid vaccine, EasyFourPol. This pioneering vaccine offers protection against five serious diseases and significantly streamlines the vaccination process.

What Are The Various Segments In The Multivalent Vaccines Market?

The multivalent vaccines market encapsulates several segments including:

1 By Type: Conjugate Vaccines, Inactivated And Subunit Vaccines, Live Attenuated Vaccines, Toxoid Vaccines, Recombinant Vaccines
2 By Disease: Influenza, Pneumonia, Hepatitis, Meningitis, Rotavirus
3 By Route Of Administration: Oral, Injectable
4 By Age Group: Pediatrics, Adults, Geriatrics
5 By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.

About The Business Research Company
Learn More About The Business Research Company. With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Browse Through More Similar Reports By The Business Research Company:
H1N1 Vaccine Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/h1n1-vaccine-global-market-report

Meningococcal Vaccines Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/meningococcal-vaccines-global-market-report

Plant-Based Vaccines Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/plant-based-vaccines-global-market-report

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
email us here
Visit us on social media:
Facebook
X
LinkedIn

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.